Health
Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test – News-Medical.net
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expan…
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.
Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the S…
-
Noosa News22 hours agoNew self-serve style chip shop, Chip ‘n’ Mix, in Noosa becomes an instant obsession
-
General22 hours agoPoliticians asked how to Trump-proof Australia’s fragile economy on Q+A
-
Business10 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?
-
General22 hours ago‘Economic bullying’: China hits out at US protectionism